While ghrelin agonism might offer the potential to treat diabetic gastroparesis and anorexia, associated with pathological underweight and cachexia, ghrelin receptor antagonism might be of therapeutic value to decrease body weight under certain conditions of obesity, and also to improve the glucose metabolism and T2DM [13]. The gene discussed is GHRL; the disease is obesity due to melanocortin 4 receptor deficiency.